| Literature DB >> 33406413 |
Rayzel C Fernandes1, John Toubia2, Scott Townley1, Adrienne R Hanson1, B Kate Dredge3, Katherine A Pillman3, Andrew G Bert3, Jean M Winter1, Richard Iggo4, Rajdeep Das5, Daisuke Obinata6, Shahneen Sandhu7, Gail P Risbridger8, Renea A Taylor9, Mitchell G Lawrence10, Lisa M Butler11, Amina Zoubeidi12, Philip A Gregory13, Wayne D Tilley1, Theresa E Hickey1, Gregory J Goodall14, Luke A Selth15.
Abstract
Potent therapeutic inhibition of the androgen receptor (AR) in prostate adenocarcinoma can lead to the emergence of neuroendocrine prostate cancer (NEPC), a phenomenon associated with enhanced cell plasticity. Here, we show that microRNA-194 (miR-194) is a regulator of epithelial-neuroendocrine transdifferentiation. In clinical prostate cancer samples, miR-194 expression and activity were elevated in NEPC and inversely correlated with AR signaling. miR-194 facilitated the emergence of neuroendocrine features in prostate cancer cells, a process mediated by its ability to directly target a suite of genes involved in cell plasticity. One such target was FOXA1, which encodes a transcription factor with a vital role in maintaining the prostate epithelial lineage. Importantly, a miR-194 inhibitor blocked epithelial-neuroendocrine transdifferentiation and inhibited the growth of cell lines and patient-derived organoids possessing neuroendocrine features. Overall, our study reveals a post-transcriptional mechanism regulating the plasticity of prostate cancer cells and provides a rationale for targeting miR-194 in NEPC.Entities:
Keywords: FOXA1; lineage plasticity; miR-194; microRNA; neuroendocrine prostate cancer; post-transcriptional gene regulation; prostate cancer; transdifferentiation
Mesh:
Substances:
Year: 2021 PMID: 33406413 DOI: 10.1016/j.celrep.2020.108585
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423